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SUMMARY
This case report focuses on a 71-year old patient affected by
unknown dyspnea and erythrocytosis referred by his general
practitioner to our center for specialist advice after a hema-
tological examination had excluded polycythemia vera on
grounds of negative test for JAK2 V617F / exon 12 mutation.
An accurate clinical history and physical examination accom-
panied by respiratory function tests resulted in diagnosis of
JAK2 V617F mutation negative erythrocytosis, and treatment
could be started. The discussion examines decisional algo-
rithms when a polyglobulic patient is referred for diagnosis.
Keywords: Dyspnea, erythrocytosis, JAK2 V617F, poly-
cythemia, pulmonary function tests.
RIASSUNTO 
Questo case report si riferisce ad un paziente di 71 anni, invia-
to dal suo medico di medicina generale alla nostra osservazio-
ne per dispnea di natura da determinare ed eritrocitosi, dopo
essere stato sottoposto a consulenza ematologica ed avere
escluso la presenza di policitemia vera con riscontro di test
negativo per mutazione gene JAK2 V617F / esone12.
Un’attenta valutazione della storia clinica ed un accurato esa-
me obiettivo, insieme a semplici test di funzionalità respira-
toria, avrebbero consentito una rapida diagnosi permettendo
l’inizio di una terapia adeguata. Vengono discussi gli algoritmi
decisionali applicabili ai pazienti poliglobulici. 
Parole chiave: Dispnea, eritrocitosi, JAK2 V617F, policitemia,
test di funzionalità polmonare.    
CLINICAL CASE
A 71-year old patient, male, former shepherd and
farmer with seasonal periods spent at high altitude
(3000 m), ex-smoker (60 pack/years), was referred
by his general practitioner to our center for special-
ist consultation after being referred for a hematolog-
ical visit because of erythrocytosis. The hematolog-
ical examination excluded the diagnosis of poly-
cythemia vera after a negative test for JAK2 V617F /
12 exon mutation.
Medical history: A liver hydatic cyst was removed
in 1984. Hypertension was treated from 1998.
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Cerebrovascular disease with two strokes and con-
sequent left partial hemiparesis occurred in 2006
and 2008. The patient was treated with beta blocker
(atenolol 100 mg), angiotensin receptor blocker and
thiazide diuretic (irbesartan 300 mg, hydroclo -
thiazide 12.5 mg); dyslipidemia was treated with
hypolipidemic drugs (atorvastatin 20 mg); he was
on therapy with anticoagulants (warfarin 5 mg) ac-
cording to the international normalized ratio (INR).
A test for the JAK2 V617F / 12 exon mutation was
performed, with negative result, after an incidental
finding of erythrocytosis (Hb 19.8 mg/dL, hemat-
ocrit 58.8%, RBC 6.9 x 106) after the patient had
been living at high altitude (about 3000 meters).
Chest x-ray and chest CT scan documented subseg-
mental dysventilation areas in the posterior part of
the lower left lobe with no expansive lesions or
lymphoadenopathies with lifting of left hemi -
diaphragm (signalled in previous chest x-ray in
2008). Snoring without referred sleep apnea was re-
ported. Abdominal ultrasonography showed en-
larged liver with colelithiasis.
Physical examination: height 1.62 m, weight 76 Kg,
body mass index 28.9 kg/m2. Pulsoximetry 91%
(ambient air). Pulse rate: 62 rhythmic; blood pres-
sure: 140/95 mm Hg; thoracic examination: sym-
metrical hemithorax, slightly sour vesicular murmur
spread over all lung fields, reduced at the left base.
Reduced motility of left hemidiaphragm. Cardiac
examination: valid rhythmic heart sounds, appar-
ently free of pauses. Abdominal examination:
tractable abdomen, painless, hypochondriac organs
within the limits. No lower limb edema.
Neurological examination: outcomes of left hemi-
paresis.
At this time (Figure 1) a complete respiratory function
study, blood gas analysis and nocturnal (8 channels)
cardiopulmonary monitoring were scheduled. 
Pulmonary function tests (Figure 2) revealed: “mild
restrictive alteration without bronchial obstruction.
erythrocytosis 
FIGURE 1: ALGORITHM FOR SUSPECTED ERYTHROCYTOSIS WHEN LEUKOCYTOSIS, THROMBOCYTOSIS, OR SPLENOMEGALY
IS NOT PRESENT
From [7] mod.
Mild alteration of lung diffusion test for carbon
monoxide (DLCO) after correction for reduced lung
volumes. Regular ventilatory pattern. Normal oc-







































Forced expiration Ref CI
FVC Liters 3.15 1.00
FEV
1
 Liters 2.42 0.84
FEV
1






 L/sec 1.04 1.28
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  Ref CI
VC Liters 3.24 0.92
FRC PL Liters 3.34 0.99
RV Liters 2.45 0.67
ERV Liters
TLC Liters 5.86 1.15





FIGURE 2: SPIROMETRY AND PLETHYSMOGRAPHIC LUNG VOLUMES IN THE STUDIED PATIENT
Definition of abbreviations: Chg, change; ERV, expiratory reserve volume; FEF, forced expiratory flow; FEV1, forced expiratory volume in
1 second; FET, forced expiratory time; FIF, forced inspiratory flow; FRC PL, functional residual capacity measured with plethysmograph;
FVC, forced vital capacity; IC, inspiratory capacity; Meas, measured; PEF, peak expiratory flow; PEFT, peak expiratory flow time; Ref, ref-
erence value; RV, residual volume; TLC, total lung capacity; VC, vital capacity.
Parameter Obstructive Central Mixed All apneas Hypopnea All events
Number 25 0 0 25 2 27
Per hour 3.6 0.0 0.0 3.6 0.3 3.9
Mean duration 
(mm:ss)  0:17 0:000 0:000 0:17 0:25 0:18 
Maximum  0:35 0:00 0:00 0:35 0:28 0:35
duration (mm:ss) (23:22:53) (-) (-) (23:22:53) (22:31:07) (23:22:53)
Apnea Hypopnea      3.9  
Index (AHI) 
RESPIRATORY EVENTS























tory and expiratory pressure (MIP and MEP)”. 
Blood gas analysis showed PaO2 52.7 mm Hg;
PaCO2 45.9 mm Hg; pH 7.40; oxhyhemoglobin sat-
uration 85.9%; carboxyhemoglobin 2.1%; methe-
moglobin 1%; P50 (partial pressure of oxygen at
which 50% of hemoglobin is saturated with oxy-
gen) 24.9 mm Hg. 
Nocturnal (8 channels) cardiopulmonary monitor-
ing (Figure 3) showed low apnea-hypopnea index
(AHI: 3.9 events/hour) with low mean nocturnal 
hemoglobin saturation (86%) and 65% of the night
spent with values below 90%.
A 6-minute walking test (Figure 4) showed 275 me-
ters walking distance with slight desaturation below
90% at the beginning of the test.
DIAGNOSIS
Dyspnea and erythrocytosis secondary to hypox-
emia in restrictive lung disease.
TREATMENT
The patient started oxygen therapy 1.5 L/min by
nasal cannula in the night. Blood gas analysis
showed no increased levels of carbon dioxide dur-
ing oxygen therapy and a nocturnal cardio -
pulmonary monitoring showed reduction of time
spent with SpO2 < 90% from 69% to 13%. Oxygen
was then increased to 2 L/min. After 2 months
hematocrit was reduced to 51% and hemoglobin
was reduced to 17 g/dL. 
DISCUSSION 
Traditionally, polycythemia has been used to identify
a group of several disorders with an increase in cir-
culating red cells and persistently raised hematocrit
(Hct) [1]. Since only the red cell lineage is involved,
in this article we have chosen to use throughout the
term erythrocytosis. Polycythemia is intended in re-
lation to the clonal disorder, polycythemia vera (PV),
in which three cell lineages are involved. In practice
it is useful to classify erythrocytosis as being congen-
ital or acquired [2,3] (Table I).







 Distance BP  RR
 bpm % m mm Hg
min 0 60 91 0 130 80 20
min 2 90 89 100 0 0 0 
min 4 45 90 195 0 0 0
min 6 75 92 275 0 0 0








FIGURE 4 : 6-MINUTE WALKING TEST DATA
Definition of abbreviations: Bpm, beats per minute; BP, arterial blood pressure; HR, heart rate; RR, respiratory rate; SpO2, oxyhemoglobin
saturation.
TABLE I: CLASSIFICATION OF ERYTHROCYTOSIS    
1. Congenital erythrocytosis
a. Associated with reduced P50 (partial pressure of oxygen at
which 50% of hemoglobin is saturated with oxygen)
i. High-oxygen-affinity hemoglobinopathy 
ii. 2,3-bisphosphoglycerate 
iii. Methemoglobinemia
b. Associated with normal P50
i. VHL gene mutations including Chuvash 
ii. Erythropoietin receptor mutations 
2. Acquired erythrocytosis
a. Clonal (polycythemia vera)
b. Secondary
i. Hypoxia driven
1. Chronic lung disease
2. Right-to-left cardiopulmonary shunts
3. High-altitude habitat
4. Tobacco use/carbon monoxide poisoning
5. Sleep apnea/hypoventilation syndrome
6. Renal artery stenosis
ii. Hypoxia independent
1. Use of androgen preparations/erythropoietin injection
2. Post-renal transplant
3. Cerebellar hemangioblastoma/meningioma
4. Pheochromocytoma/uterine leiomyoma/renal cysts/
parathyroid adenoma































6 greater than 2-3 standard deviations from the age,
sex and race-adjusted predicted values in hematocrit
or hemoglobin level. Patients with a persistently
raised venous hematocrit (Hct) (> 0.52 males, 
> 0.48 females for > 2 months) should, in general,
be investigated by means of a complete evaluation of
all cell lines and blood plasma volume and an accu-
rate anamnestic investigation is essential to identify 
possible causes of differential diagnosis (current or
past cigarette smoking, living at high altitude, congen-
ital heart disease, chronic respiratory disease, sleep
apnea, kidney disease, peptic disease) [2,4,5].
If there are clinical and medical history data that
suggest an acquired erythrocytosis secondary to res-
piratory disturbance, World Health Organization
(WHO) diagnostic criteria [5] recommend to pro-
ceed with several laboratory and instrumental in-
vestigations, starting from hemoglobin saturation
evaluation and continuing if hemoglobin saturation
is normal with exclusion of mutation of JAK2 V617F
/ exon 12. If negative, measurement of the serum
levels of erythropoietin is proposed to rule out cases
in which renal disease or cancer are present. If the
erythropoietin results normal or decreased, the 
diagnosis is directed towards polycythemia vera.
Today we know that 95% of patients with poly-
cythemia vera carry the mutation of JAK2 V617F /
exon 12. Hence, evaluation of the mutation has be-
come one of the key steps in the diagnosis of this
disease, but it is not useful for distinguishing one
myeloproliferative disease from another, since it has
been found in patients with essential thrombo-
cythemia, primary myelofibrosis and other myeloid
malignancies, and, in some cases, is associated
with abnormal levels of erythropoietin [4,5]. Bone
marrow biopsy is therefore important, as it is the
only analysis that defines the predominant type of
cell proliferation in order to assess the presence of
marrow fibrosis (Figure 1) [6].
It should also be borne in mind that "false positives"
are not uncommon; in fact the new standard criteria
of WHO in 2008 have included minor diagnostic
criteria to enhance the molecular diagnosis of poly-
cythemia vera [7].
Currently, analysis of JAK2 V617F / exon 12 muta-
tion is not so expensive (200 euros in our hospital)
but in many centers the determination is not poss -
ible or requires longer time. Application of a correct
algorithm can simplify in many cases the diagnosis
when a secondary cause of erythrocytosis is pres-
ent, allowing a faster and appropriate treatment.
If the erythrocytosis - as in the present case - is sec-
ondary to respiratory disease, pulmonary function
tests, blood gas analysis and nocturnal saturation or
sleep study (if the patient is obese or excessive day-
time sleepiness is present) are indicated [8]. In this
case treatment consists in oxygen therapy or contin-
uous positive airway pressure treatment if sleep dis-
turbance is present [3,9,10].
CONCLUSIONS
In our case, an accurate anamnestic and careful ob-
jective examination (erythrocytosis, low hemoglo-
bin saturation, hypoxemia and hypomobility of the
left hemidiaphragm) could have led immediately to
a clinical diagnosis of secondary erythrocytosis and
would have avoided the implementation of further
tests such as analysis of JAK2 V617F / exon 2 muta-
tion with delay in the diagnosis and treatment.
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